The impact of older age and duration of diabetes mellitus on macrovascular complications is unclear.
T he worldwide prevalence of diabetes mellitus is increasing, partly as a result of increasing overweight and obesity and also due to the increasing proportion of older adults in whom the incidence of diabetes is highest (1, 2) . In 2011, 346 million people were living with diabetes, 90% of whom had type 2 diabetes (3). Diabetes is associated with increased mortality from all-causes, and from cardiovascular disease (CVD) and cancer (4 -6) . The degree to which diabetes shortens life expectancy is a function of age. At 40 years age, diabetes reduces life expectancy by six years, the disparity diminishing with age as life expectancy falls until it is minimal at 90 years age (7) . The incidence of several diabetes-related vascular complications has declined between 1990 and 2010 but the burden of ill-health attributable to diabetes-related complications remains high as the prevalence of diabetes increases (8) .
Despite the increasing proportion of older persons with diabetes, the relationship between diabetes duration and risk of major vascular complications in this population remains unclear. In young adults with type 2 diabetes, increasing duration of diabetes correlates with increased carotid intima-media thickness (9) . In adults newly diagnosed with type 2 diabetes, goals of therapy are to lower blood glucose levels and thus prevent microvascular and macrovascular complications (10) . However, trials of intensive glucose-lowering including older patients with type 2 diabetes of longer duration failed to reduce cardiovascular events (11) (12) (13) . Current recommendations for care of patients with type 2 diabetes emphasize the need to personalize therapy and suggest consideration of less stringent targets for patients with advanced age and longer duration of diabetes (14) . Clarifying whether the risk of major cardiovascular events in adults who are diagnosed with diabetes in middle and older ages is stable over time, or progressively increases with diabetes duration independently of age, would inform evaluation of benefits vs risks of treatments to lower vascular risk in the expanding population of older adults living with diabetes.
We tested the hypothesis that in older adults, duration of diabetes influences the incidence of major cardiovascular events independent of age and differently from prior cardiovascular events. We compared the influence of diabetes duration on the incidence of myocardial infarction (MI) and stroke, with the influence of prior MI and stroke to determine whether these were comparable or distinct risk predictors of death and cardiovascular events.
Materials and Methods
The recruitment of participants has been described in depth previously (15, 16) . Briefly, between March 1996 and January 1999, 19 352 men aged 65 years and older were randomly selected from the electoral roll (enrolment to vote being compulsory for Australian citizens) and invited to join a screening trial for detection of abdominal aortic aneurysm (AAA). The target population for the initial study was a random sample of community-dwelling men aged Ն 65 years. Of these, 12 203 men (63.1%) attended a clinic and completed a questionnaire that assessed a range of demographic and clinical data. Each man had their height, weight, and blood pressure (BP) measured, and completed a questionnaire assessing history and lifestyle including smoking status, alcohol consumption, exercise, dietary habits, history of (or treatment for) coronary heart disease (CHD), stroke or transient ischemic attack, hypertension, dyslipidemia or diabetes. Participants were predominantly Caucasian. Men provided written informed consent to participate in the study and to have extended follow-up of their health outcomes. The study was approved by the Human Research Ethics Committee of the University of Western Australia.
Diagnosis of diabetes mellitus
Questionnaire data were used to identify men with diabetes. Men were asked (a) whether a doctor or nurse had told them they had diabetes, if so their age when first told, (b) whether they had ever been given advice or treatment for diabetes, if so their age when this occurred, (c) what kind of advice or treatment they received when diagnosed, and (d) what kind of advice or treatment they were receiving for diabetes at the time of questioning. Men who had been diagnosed with the condition, or reported use of glucose-lowering medication were considered to have diabetes. Duration of diabetes was determined by subtracting the present age from the age of onset of diabetes.
Definition of cardiovascular risk factors and disease
Men were asked whether they had ever been told they had any of the following: high BP, high cholesterol, angina, heart attack, heart bypass surgery, heart balloon angioplasty or stroke. Men were asked whether in the last month they had been taking tablets for BP, angina, or high cholesterol, and whether they were on a diet prescribed by a doctor or dietician to lower blood cholesterol levels.
Outcomes of interest
We assessed outcomes via the Western Australian Data Linkage System (WADLS), which provides electronic linkage to records from death, hospital, and cancer registries and captures admissions to all public and private hospitals in Western Australia (17) . WADLS linkage based on ICD-10 or equivalent coding has comparable accuracy to adjudication of medical records (18) . Occurrence of death was ascertained from WADLS, which contains both the original death certificate and an ICD-10 coded record generated from these data and from other sources, such as the Australian Bureau of Statistics. Follow-up data were available until the December 31, 2010. The primary outcomes were the occurrence of death from any cause, and incidence of hospital admissions or deaths associated with a recorded diagnosis of MI or stroke.
Statistical analyses
We used Stata version 11.1 to analyze the data (StataCorp). Descriptive data are shown as number (%). For survival analyses, we used age at risk as the analysis time so that the baseline hazard in the regression models was the age-specific hazard. All duration variables (time since onset of diabetes, or time since the occurrence of the initial MI or stroke) were fitted as time-dependent to ensure that these variables accurately reflected the duration of each exposure when outcome events occurred. For example, a man who had diabetes for 20 years at study entry and died 10 years later; had duration of diabetes of 30 years at the time of death. Cox proportional hazards regression was used for analyses where all-cause mortality was the outcome of interest. Competing risks regression was used for the cause-specific analyses, according to the method of Fine and Gray (19) . For the outcome of deaths due to MI, and the outcome of fatal and nonfatal MI, competing risks were non-MIrelated mortality. For the outcome deaths due to stroke, and the outcome of fatal and nonfatal stroke, competing risks were nonstroke-related mortality. Analyses were adjusted for smoking, education, alcohol use, exercise, body mass index (BMI), hypertension, and elevated cholesterol. Results were tabulated or plotted graphically using restricted cubic splines as hazard ratio (HR) and 95% confidence interval (CI).
Results

Baseline characteristics of the study population
Complete baseline and follow-up data were available for 11 728 men. There were 1433 men (12.2%) with diabetes of whom 208 (14.5%) reported their age of onset as Ͻ 55 years, 451 (31.5%) as 55-64 years, 679 (47.4%) as 65-74 years with 95 (6.6%) reporting onset at age Ͼ 74 years. The baseline characteristics of the study population are shown in Table 1 . Compared with nondiabetic men, men with diabetes were more likely to have had an MI or stroke above the age of 50 years, tended to be older when stopping smoking, completed their education earlier, reported higher alcohol consumption, less exercise, and had greater prevalence of obesity and treatment for hypertension and high cholesterol. Age, exercise, BMI, and treatment modalities are shown in Table 2 , stratified according to age at diagnosis of diabetes.
All-cause mortality according to duration of diabetes, MI or stroke
The mean (SD) duration of follow-up was 10.6 (3.8) years (median 12.6 years, interquartile range 8.3-13.3 years). Diabetes was associated with increased all-cause mortality with an age-specific HR of 1.37 (95% CI ϭ 1.15-1.62) for diabetes duration of 5-9 years, 1.35 (1.18 -1.55) for 10 -14 years, 1.42 (1.22-1.66) for 15-19 years, and 1.75 (1.45-2.11) for 20 -24 years (Table 3 ). The time since a prior MI was associated with all-cause mortality, with the highest age-specific HR being 2.31 (95% CI ϭ 1.61-3.30) within 5 years of the prior event. The time since a prior stroke was associated with increased all-cause mortality for a circumscribed period of 5-24 years after the event (HR ϭ 1.77, 95% CI ϭ 1.48 -2.10 at 5-9 years after the stroke). When duration of diabetes was analyzed continuously, the age-specific HR and 95% CI rose to a plateau after 20 years duration (Supplemental Figure 1, A) . Increasing interval since a prior MI was associated with increased mortality risk, but mortality peaked at 10 -15 years following a prior stroke and declined thereafter (Supplemental Figure S1 , B and C).
MI-specific mortality and events, according to duration of diabetes, MI or stroke
The age-specific HR and 95% CI for fatal MI are shown according to duration of diabetes, time since prior MI and time since prior stroke ( Figure 1, A-C) . There was an increased risk of fatal MI with diabetes duration up to 25 years. Risk of fatal MI increased following prior MI reaching a higher plateau around 20 years ( Figure 1B) . Prior stroke increased MI-specific mortality to a lesser degree compared with prior MI.
When the combined endpoint of fatal and nonfatal MI was analyzed (Figure 1, D-F) , there was an increase in the risk of MI with diabetes duration with a plateau at 20 years ( Figure 1D ). Prior MI increased the risk of subsequent MI with a clearly defined peak at 15-20 years (Figure 1E) . Prior stroke increased the risk of subsequent MI to a lesser extent than prior MI for a period of 5-24 years after the stroke ( Figure 1F ).
Stroke-specific mortality and events, according to duration of diabetes, MI or stroke
The age-specific HR and 95% CI for fatal stroke are shown according to duration of diabetes, time since prior MI and time since prior stroke (Figure 2, A-C) . The risk of fatal stroke increased progressively with duration of diabetes ( Figure 2A ). Prior MI was associated with a transient and marginal increase in risk of fatal stroke ( Figure 2B ). Prior stroke was associated with substantially increased risk of subsequent fatal stroke peaking at 15 years after the initial and diminishing thereafter ( Figure 2C ).
When the combined endpoint of fatal and nonfatal stroke was analyzed (Figure 2, D-F) , there was an increase in the risk of stroke with diabetes duration plateauing at 20 years ( Figure 2D ). Prior MI modestly increased the risk of stroke ( Figure 2E ). Prior stroke substantially increased the risk of subsequent stroke again with a peak at around 15 years ( Figure 1F ).
Analyses excluding men receiving insulin
These analyses were repeated after excluding all men receiving insulin (N ϭ 141), comprising men with type 1 diabetes or with type 2 diabetes receiving insulin therapy. The results were essentially unchanged (data not shown).
Sensitivity analyses
Exclusion of men with CVD at baseline did not appreciably alter the associations of diabetes duration with allcause mortality (data not shown). After excluding men with prior CVD, the association of diabetes duration with deaths from MI was accentuated for duration up to 20 years and attenuated thereafter ( Figure 3A) , while the association of diabetes duration with stroke events (nonfatal and fatal) became more prominent ( Figure 3D ). 
Discussion
In community-dwelling men aged Ն 65 years, a diagnosis of diabetes predicted increased all-cause mortality, and incidence of MI and stroke. Increasing duration of diabetes was associated with stable increases in age-specific mortality and mortality from MI in these older men. However increasing duration of diabetes was associated with progressively higher mortality from stroke. The increased incidence of fatal and nonfatal MI and stroke events was stable with increasing diabetes duration. Prior MI and stroke were associated with excess mortality risk; and with increased incidence of subsequent MI and stroke peaking at 10 -20 years following the initial event. These results are consistent with diabetes being a duration-dependent risk factor for cardiovascular events in older men, which influences risk differently from prior MI or stroke. Type 2 diabetes is a recognized predictor of mortality from all causes including from CVD (4 -7). However, the evolution of diabetes-attributable risk over time remains unclear. In a study of 14 374 adults aged 25-74 years, age-adjusted mortality was higher for those with diabetes duration Ն 15 years compared to 5-14 or Ͻ 5 years, but the relative mortality risk attributable to diabetes was lower in 65-74 year-old men and highest in 25-44 year olds (4) . Another study reported a higher absolute mortality rate for the diabetic compared with the nondiabetic population, with the increased relative mortality risk in diabetic adults diminishing by the age of 75 years (20) . The AusDiab study reported increasing mortality over time, with a steeper gradient for adults with diabetes and elevated mortality risk in both 45-64 and Ն 65 year olds (21) . Therefore it was unclear whether increasing duration of diabetes continues to contribute to increased mortality in older adults, or whether this was overwhelmed by the age-associated increase in mortality rate.
The difficulty in dissecting out the contribution of diabetes duration to the risk of macrovascular events is twofold. Firstly, age, age at onset of diabetes and duration of diabetes are inter-related, as age is the sum of the other two variables (22) . Secondly, duration of diabetes increases linearly with age. Therefore, these variables cannot be modeled as independent factors. Using an age-specific HR, we found in older men consistent and stable increases in risk of mortality, MI and stroke attributable to diabetes with duration of five years or more. There was no decline in the age-specific mortality relative to nondiabetic men with increasing duration of diabetes, suggesting that the influence of diabetes on mortality risk does not diminish with age. Thus, models in which the excess in diabetesattributable mortality narrows with increasing age may reflect the diminishing life expectancy of older adults rather than a more benign course of diabetes. Our results differ from trends observed for the contribution of other risk factors to CVD-related deaths. For instance, the Prospective Studies Collaboration reported that increasing total cholesterol levels correlated with increased HR for mortality from ischemic heart disease; at increasing age strata the absolute HR was higher but the gradient of the slope was less pronounced (23) . The contribution of this risk factor was attenuated in the oldest subjects who have the highest background risk. In our study, the increase in deaths and macrovascular events manifests relatively soon after the diagnosis of diabetes and the influence of diabetes on these outcomes is stable and durable even in older men.
These results contrast with findings from the Framingham Heart Study in 588 adults with diabetes and a mean age of 59 years in which risk of CHD death was increased per 10-year increase in duration of diabetes, but all-cause mortality was not (24) . In a prospective study of 4045 men aged 60 -79 years followed for 9 years, men with later onset of diabetes (diagnosed at Ն 60 years, corresponding to duration of 4.9 years) had a CHD risk approximately half that of men with earlier onset of diabetes (diagnosed at Ͻ 60 years, corresponding to duration of 16.7 years) (25) . These studies identified either an earlier onset of diabetes or an extended duration of disease as a CHD risk factor. Our results indicate that, in older men, at any given age there is increased risk of death from any cause as well as MI attributable to diabetes for duration greater than five years. The increased risk for death from any cause remains stable and does not diminish with further increases in diabetes duration.
Analysis of risk according to duration of exposure provides additional information on the comparability of diabetes to prior MI as predictors for subsequent cardiovascular events. Previous studies have postulated the equivalence of diabetes to prior MI as a predictor of cardiovascular-related mortality (26, 27) . However, other studies indicated a greater influence of prior MI compared to diabetes for CHD-related mortality or events (28, 29) . The Health Professionals Study of 51 316 men aged 40 -75 years reported lower relative risks for fatal CHD in men with diabetes compared to nondiabetic men with MI (28) . In that study the relative risks for all-cause mortality were comparable for both groups. Lee et al followed 13 790 adults aged 45-64 years from the Atherosclerosis Risk in Communities Study for an average of nine years, finding an almost twofold higher risk of fatal or nonfatal MI for those with MI and no diabetes compared to those with diabetes (29) . Our results indicate that the contributions of diabetes and prior MI to subsequent CVD event risk differ not only in magnitude but also over the course of time following the diagnosis of diabetes, MI or stroke.
In our study diabetes was associated with a modest increase in the age-specific risk of MI-specific mortality and MI events in men, which was apparent after five years diabetes duration and stable thereafter. By contrast, prior MI was associated with a larger age-specific risk of MIrelated deaths and events, and this peaked 15-20 years after the initial MI and subsequently declined. These findings extend the previous report by Vaccaro et al in which age-adjusted mortality risk in middle-aged men with diabetes was consistently lower compared to men with prior MI over an extended duration of follow-up (30) . Our results contrast with the study by Pajunen et al in in which diabetes conferred a lower risk than prior MI in men aged Յ 64 years, but a slightly higher risk in men aged Ն 65 years (31) . However, in that study the numbers of men in the 65-74 year age stratum was limited.
Zoungas and co-workers recently reported an association of diabetes duration with the risk of macrovascular events, microvascular events and death in participants in the ADVANCE trial (32) . In that study, age or age at diagnosis and diabetes duration were related to study outcomes and all participants had type 2 diabetes as an inclusion criterion for the parent trial. Our approach differs as we studied a population-based cohort of older men, allowing us to assess the excess risk attributable to diabetes and the influence of diabetes duration on deaths, MI, and stroke compared to men without diabetes. Furthermore, we compared associations of diabetes, prior MI, and prior stroke with these outcomes according to duration of time elapsed since the diagnosis of diabetes, and the occurrence of the first MI or stroke.
We found that MI was a relatively weak predictor of subsequent stroke, and vice versa. This may reflect the differing aetiologies of these events and differences in the underlying vascular territories. MI involves ischemic events due to unstable atherosclerotic plaque and thrombosis in coronary arteries, while stroke can be either ischemic or hemorrhagic, and involves events arising in extra-and intra-cranial arteries which exhibit differences in anatomy, physiology and responses to risk factors (33, 34) . Of note, increasing diabetes duration predicted a progressively increased risk of mortality from stroke, and a stable increase in stroke events. The finding that diabetes-associated risk of subsequent MI or stroke did not diminish with increasing duration of diabetes compared to the peak in corresponding event risk 15 years after the initial MI or stroke is of interest. This may reflect differences in modulation of vascular pathophysiology by diabetes (35) or possibly greater success of medical therapy for secondary prevention of MI and stroke (36) . Improvements in management of risk factors and overall medical care may be contributing to a narrowing in the mortality gap between diabetic and nondiabetic individuals (37, 38) , yet extended duration of diabetes remains a contributor to macrovascular events in the older demographic where its prevalence is highest. Strengths of our study include the large, populationbased sample, the focus on older men, the extended period of follow-up, the characterization of comorbidities allowing adjustment for other CVD risk factors in the analyses and the integrity of the follow-up using data linkage via the WADLS. Because the WADLS captures outcomes for the entire state of Western Australia and few men of this age emigrate, loss to follow-up due to cross-boundary flows is minimal (17) . As age is the sum of age at onset and duration of diabetes, we used age-specific hazard as the basis for the analysis and duration of diabetes as the independent variable, tabulating HR and CI. This approach offers a means to dissect out the association of duration of diabetes to outcomes of interest at any given age. Adjustment was made for other variables, such as smoking, hypertension, and hypercholesterolemia, which could influence risk of MI or stroke (39) . We compared duration of diabetes and interval of time since an initial MI or stroke, allowing us to assess exposure over time to these three distinct conditions. We acknowledge several limitations of our work. Our study was observational in nature, therefore causation cannot be defined and there may be confounding from unknown or unmeasured variables. Diagnoses of diabetes, duration of disease and medications used to treat diabetes were based on self-report, and the questionnaire did not specify whether men were told they had type 1 or type 2 diabetes. Therefore, age of onset of diabetes may not have been recalled accurately. While we did not seek verification from treating physicians, we expect misclassification of exposure to be nondifferential with respect to the outcomes which would have attenuated the observed associations. Effect estimates may be less reliable at longer duration of diabetes and intervals since prior MI or prior stroke, as there are fewer men in these strata and hence wider confidence intervals. Most of these men would have had type 2 diabetes, with only a small minority requiring insulin whether for ␤-cell failure or to optimize glycemic control (40) . Men who had type 1 diabetes would have been on insulin therapy and exclusion of men receiving insulin did not alter the findings. We did not collect blood samples during recruitment in 1996 -1999, thus could not measure HbA1c. However, a previous study in Western Australia reported that older adults with diabetes tended to have satisfactory HbA1c levels (41) . The HIMS cohort is almost entirely Caucasian, therefore additional studies are required to extend our findings to other populations. Finally, we cannot comment on the influence of diabetes duration on these outcomes in women.
In conclusion, our results indicate that in men, diabetes continues to function as either a marker for or a contributor to macrovascular events and mortality even in advanced old age. Increased longevity does not protect against the higher risk of death, MI and stroke associated with diabetes, once diabetes has been present for longer than five years. Current guidelines support careful personalization of glucose-lowering therapy in older persons living with diabetes; and our findings indicate the risks of macrovascular disease do not diminish with increasing duration of disease. Additional research is warranted to investigate how diabetes makes distinct contributions to the pathophysiology of MI and stroke in the elderly and to explore the scope for improving stroke prophylaxis in older men with longer duration of diabetes.
